Cargando…
Case Report: Immune Checkpoint Inhibitors as a Single Agent in the Treatment of Metastatic Cervical Cancer
The incidence of cervical cancer has decreased in recent years due to widespread vaccination and routine screenings. It can be treated successfully, and the prognosis is also excellent if detected early. However, the 5-year survival rate for patients with stage IV cervical cancer is only 17% even wi...
Autores principales: | Anipindi, Manasa, Smith, Ryan J., Gilani, Madiha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019553/ https://www.ncbi.nlm.nih.gov/pubmed/35463318 http://dx.doi.org/10.3389/fonc.2022.856944 |
Ejemplares similares
-
Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022) -
Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report
por: Wu, Xiaoli, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
por: Kamath, Suneel D., et al.
Publicado: (2018) -
Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)